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Abstract
Tuberculosis (TB) is the leading cause of death from infectious disease worldwide, predominantly affecting low- and
middle-income countries (LMICs), where resources are limited. As such, countries need to be able to choose the
most efficient interventions for their respective setting. Mathematical models can be valuable tools to inform
rational policy decisions and improve resource allocation, but are often unavailable or inaccessible for LMICs,
particularly in TB. We developed TIME Impact, a user-friendly TB model that enables local capacity building and
strengthens country-specific policy discussions to inform support funding applications at the (sub-)national level
(e.g. Ministry of Finance) or to international donors (e.g. the Global Fund to Fight AIDS, Tuberculosis and Malaria).
TIME Impact is an epidemiological transmission model nested in TIME, a set of TB modelling tools available for
free download within the widely-used Spectrum software. The TIME Impact model reflects key aspects of the
natural history of TB, with additional structure for HIV/ART, drug resistance, treatment history and age. TIME Impact
enables national TB programmes (NTPs) and other TB policymakers to better understand their own TB epidemic, plan
their response, apply for funding and evaluate the implementation of the response.
The explicit aim of TIME Impact’s user-friendly interface is to enable training of local and international TB experts
towards independent use. During application of TIME Impact, close involvement of the NTPs and other local
partners also builds critical understanding of the modelling methods, assumptions and limitations inherent to
modelling. This is essential to generate broad country-level ownership of the modelling data inputs and results.
In turn, it stimulates discussions and a review of the current evidence and assumptions, strengthening the
decision-making process in general.
TIME Impact has been effectively applied in a variety of settings. In South Africa, it informed the first South African HIV
and TB Investment Cases and successfully leveraged additional resources from the National Treasury at a time of
austerity. In Ghana, a long-term TIME model-centred interaction with the NTP provided new insights into the local
epidemiology and guided resource allocation decisions to improve impact.
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The need for a country-level modelling tool in TB
Tuberculosis (TB) is now the leading cause of death from
infectious disease worldwide [1]. It is also a disease of the
poor, with the majority of the burden carried by low- and
middle-income countries (LMICs) and vulnerable popula-
tions [2, 3]. While overall incidence is falling, the current
rate of decline will not enable countries to reach the tar-
gets set by the World Health Assembly [1, 4]. Despite this
high burden, and the need for accelerated progress, na-
tional TB programmes (NTPs) in LMICs face substantial
constraints on the resources available, and are therefore
under high pressure to maximise the epidemiological im-
pact (e.g. cases prevented, lives saved) with their limited
means [5].
Modelling tools have been highly effective in supporting
country programs to make more efficient policy choices
as well as strengthening the case for investment to both
domestic and international funders [6–8], for example,
through applications to the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM). Notable examples
include the Spectrum software suite, which includes
the AIM and Goals tools, which over the past decade
have been extensively used to mobilise and direct re-
sources in HIV (Fig. 1, top row) [9, 10], AEM which is
used extensively in concentrated epidemics, and Optima,
which specializes in allocative-efficiency.
Modelling capacity is limited in most LMICs, particularly
in the area of TB. At the same time, policy decision-making
is increasingly locally-led [11]. A pre-built, customisable TB
modelling tool with a user-friendly interface could make
modelling resources more widely available for policymakers
in LMICs. By engaging in-country policymakers in the
modelling process, local ownership of the modelling
methods and results can be increased, as the process
requires an assessment of the data and epidemic, including
existing gaps, and working through the data and assump-
tions for potential interventions. Together, these benefits
strengthen the rational foundation of TB policy decisions
in LMICs [12]. In addition, a user friendly interface would
allow for building local capacity, where local TB experts
can progress from being informed consumers of modelling
results to independent users of the modelling tool.
In TB, modelling is increasingly used to inform global
[13, 14] and local TB policy [15, 16] on specific questions
or areas [17–19]. However, TB models to date have been
either limited in scope [17, 18] or developed for the use of
academics and, as such, are difficult to access by NTPs as
part of their planning process [14]. Therefore, there
remains a need for a flexible user-friendly TB tool that
could be customised to different epidemiological set-
tings, and explore TB care and prevention activities
across the NTP portfolio.
Fig. 1 TIME Impact structure and link within Spectrum software suite. Figure illustrates how the TIME Impact tool is embedded in the Spectrum
software suite, and linked to key modules and databases for demography, tuberculosis and HIV estimates (top row). The TIME box shows the
basic model structure of TIME Impact (red boxes) and how TIME Impact fits within the other TIME modules
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We developed TIME Impact as part of a flexible, free-
for-download and user-friendly TB software package to
provide an accessible and locally-owned modelling plat-
form for in-country TB policymakers. In this paper, we
describe the implementation and utility of the tool, as
well as two case studies of its application in South Africa
and Ghana.
The TIME Impact tool
TIME Impact is implemented as part of the TIME mod-
elling suite of software tools nested in the Spectrum
software package (Fig. 1). As a component of Spectrum,
TIME Impact automatically pulls in country data on TB
(from the Global TB Programme (GTB) at the World
Health Organization), HIV (from UNAIDS), and dem-
ography (based on estimates from the UN Population
Division), which greatly facilitates customising the
model to the national epidemiology (see Fig. 1, top 2 rows).
Together with the other modules in TIME (TIME Data,
TIME Estimates [20] and TIME Economics), TIME Impact
enables NTPs and other TB policymakers, who may not
have formal training in modelling, to better understand
their own TB epidemic, plan their response, provide key in-
puts for funding applications and evaluate the implementa-
tion of the response.
TIME Impact – epidemiological model
The core of TIME Impact is a dynamic compartmental
transmission model which includes latent Mycobacter-
ium tuberculosis infection and disease following recent
(re)infection and reactivation (Fig. 1, top left red box)
[14, 21]. To be useful, a principal requirement of the
TIME Impact model is flexibility in order to allow cali-
bration to different country settings, reflect historical
local TB epidemiology, project likely future trends under
current and alternative NTP intervention packages, as well
as address critical policy questions. For this purpose, the
model has been stratified by HIV and antiretroviral ther-
apy (ART) status of individuals, their multi-drug resistance
status, treatment history, as well as age to capture the
different epidemiological characteristics of paediatric
TB [22] (Fig. 1, lower right red box). Point value and
ranges for natural history parameters are based on review
of the literature (Additional file 1, section 6).
Critical for costing and understanding the value of
diagnostic tools, TIME Impact also takes into consider-
ation the population that is screened for TB. In order to
approximate screening mechanisms, we apply a method
similar to that developed by Menzies et al. [14]. The
user-implemented screening algorithm thus results in
true and false positive diagnoses, which after linking to
care, gives rise to true and false positive notifications
(see Additional file 1, section 4 for more details).
TIME Impact – interface
TIME Impact’s menu-driven interface improves the
accessibility of the model and provides the opportunity
to build technical capacity within NTPs, increasing
the likelihood of local ownership of modelling results.
Through the interface, users can explore the current
epidemic as well as the epidemiological impact of NTP
activities either by scaling-up specific TB care and pre-
vention packages or exploring custom activities (Fig. 2).
The results window allows users to look at a variety
charts and tables that contain model outputs over time,
from changes in disease burden (e.g. prevalence, inci-
dence, mortality), to specific TB epidemic dynamics (e.g.
proportion latently infected, proportion due to recent
transmission, annual risk of infection) and programmatic
outputs (e.g. notifications, number screened, positive
predictive value of the diagnostic algorithm). Through
these outputs, users can see how the modelled epidemic
changes over time, and whether historical trends are
reflected sufficiently to increase confidence of the model’s
projection of impact from future activities.
Estimating the epidemiological impact of NTP activities
Activities to improve TB care and prevention can be
modelled in two ways in TIME Impact, either by making
use of the intervention window to incorporate potential
NTP activities or by manipulating the care and control
parameters to reflect the expected effect and scale-up of
existing or alternative NTP activities.
Examples of pre-specified activities include periodic
TB screening of people living with HIV (ART naïve, or
on ART) followed by preventive therapy, or providing
HIV testing and ART initiation for diagnosed TB cases;
household contact screening, with the provision of iso-
niazid preventive therapy to under 5 year olds in contact
with an index case.
Alternatively, users can capture the epidemiological
impact of interventions by manipulating the care and
control parameters in TIME Impact. Such activities include,
but are not limited to, different clinic-based screening
activities (i.e. expanding the population eligible for TB
screening) and the roll-out of new diagnostic algorithms
(which would be applied to those being screened).
It is important to emphasize that, for such custom
interventions, a comprehensive dialogue between the
modelling team and country stakeholders is critical to
establish a shared understanding of the proposed activ-
ities, their expected effect and the data and assumptions
that have been used to calculate this effect.
Further, to enable evaluation of a wide range of inter-
vention activities, and to keep the tool as simple as pos-
sible, the level of detail within each intervention area is
necessarily limited. Consequently, TIME Impact is not
set up to address detailed operational questions on what
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diagnostic algorithm to use at each clinic level. Such
questions could be tackled using other applications such
as an ad-hoc operational tool, informed or guided by the
WHO ScreenTB tool [18, 19]. TIME Impact can high-
light the need for such an analysis, and incorporate the
outcomes where relevant in the epidemiological model.
Use of TIME Impact in-country
Users and consumers of TIME Impact
TIME Impact has been designed as a modelling tool that
can be used by non-modellers, e.g. trained TB epidemiolo-
gists such as selected NTP staff or (inter)national consul-
tants. Users can then collaborate with key stakeholders and
partners who know the local TB epidemiology, on how best
to maximize access to the available data and effectively inte-
grate within the policy decision process.
TIME Impact structure and results are tailored to
‘consumers’ within NTPs and other in-country policy-
makers, as they consider programming their TB-specific,
or joint TB/HIV, response, as well as stakeholders and
partners who support the process. These actors can make
use of the TIME Impact results for the prioritisation of
activities, preparation of a National Strategic Plan, and
preparation of funding requests, either domestically to
the Ministry of Finance or from bi-lateral and multi-
lateral international donors.
Through training, which is enabled by TIME Impact’s
user-friendly interface, key individuals can cross the line
between informed consumers of TIME Impact modelling
results towards independent users of the model, using it
independently to address locally-generated questions, and
take full ownership of and accountability for the results.
TIME Impact as part of the NTP programming cycle
In order to maximise the utility of TIME Impact, it should
be used as part of the NTP programming cycle within a
coherent decision-making framework, which links the
model with relevant stakeholders and the country’s
programming cycle of assessing the situation, planning
a response, applying for funds, implementing interven-
tions and evaluating their impact (Fig. 3) [23].
Modelling complements an epidemiological assessment
of the impact of past activities and supports the situational
analysis of current burden by generating epidemiological
evidence to inform the prioritisation of country needs.
During the planning phase, TIME Impact modelling can
be used to explore the epidemiological impact of different
potential activity programmes, which feed into resource
allocation and allocative efficiency models. The process
leads to a more rational NTP which has been informed by
the modelling results and lessons learnt from, for example,
the epidemiological assessment. When applying for funds,
modelling can support the decisions for prioritisation of
activities that are now considered fundamental to invest-
ment case analyses and funding applications such as those
submitted as part of the GFATM concept note process.
Fig. 2 TIME Impact interface. TIME Impact’s user-friendly interface enables technical capacity building within National Tuberculosis Programmes.
The user works through the different windows of (1) epidemiology, (2) care and control, and (3) interventions before visualising results (see drop
down menus)
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Modelling can be used to track the implementation of pol-
icies and coverages in the model can be adjusted based on
coverages achieved. For evaluation, programmatic achieve-
ments, e.g. notifications achieved, can be checked against
the modelled projection. Similar to the framework recently
suggested by Knight et al. [12], a key feature is on-going
engagement with all actors in the policy process, through-
out the policy cycle. This cyclical health policymaking
framework using modelling leads to a better understand-
ing of the epidemic and a better understanding of the re-
sponse for more effective policies that are supported by
locally-generated evidence.
TIME Impact provides the opportunity to bring together
different actors in the policy process who have a shared
objective to reduce TB burden, but may offer diverse per-
spectives, allowing for a wider range of voices to be con-
sidered when interpreting evidence. These actors include
governments (e.g. Ministry of Health), bilateral agencies
(e.g. USAID, DFID), funding organisations (e.g. Global
Fund) and academia (e.g. modelling experts), but this list
is non-exhaustive [24].
The model serves as a focal point for discussions, with
the TIME Impact model, current policies, and the evi-
dence that support them at the centre of the dialogue
for well-informed decision making. TIME modelling
uses a mechanism that forces discussions on elucidating
all assumptions, making the modelling and policy process
transparent, thus building shared understanding of the
results. Holding these discussions in a transparent way
across the network of actors can be of great benefit to
reach consensus, increase broad ownership of the mod-
elling results, rationalise targets and objectives, and
strengthen overall policy decisions [25].
Data needs
When considering data requirements for TIME Impact,
one needs to consider the natural history of TB, data for
care and prevention (programmatic data, such as notifica-
tions, linkage to care, treatment success), and epidemio-
logical data (e.g. prevalence or drug resistance survey) or
estimates (e.g. incidence and mortality). Furthermore, data
needs can be separated into inputs (data that get inputted
into the model to influence the modelled epidemiology)
and outputs (data that the modelled epidemiology are
checked against). Table 1 highlights the data that are desir-
able, essential and automatically available.
Through its links within Spectrum, TIME Impact
automatically imports official national-level country data
on TB (from GTB), HIV (from UNAIDS) and demography
(from UN population division), to facilitate customising
Fig. 3 TIME Impact as part of the National Tuberculosis Programme (NTP) programming cycle. Figure and table illustrate how the TIME model
can be a central focus of the NTP programming cycle and can support the process at each stage
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the model to the local setting. In some cases, sub-national
level data are available, e.g. with UNAIDS HIV estimates,
which facilitates the application of TIME Impact at sub-
national level.
Care and control parameter data are also model in-
puts, which come from programmatic data that describe
the screening algorithms used, what proportion of patients
diagnosed with TB are linked onto care and successful
treatment outcomes.
Where possible, context specific data on the expected
epidemiological impact of interventions is also desirable,
though often unavailable for TB.
Country case studies of TIME Impact
The TIME Impact software tool is now available for free
download at http://www.TIMEmodelling.com. It has
been applied successfully at various points in NTP
programming cycle, exploring different aspects of the
tool’s functionality. Across divergent settings in terms
of epidemiology and policy debate, TIME Impact was
able to capture the local TB epidemic and reflect historical
trends, and projections were used to guide policy discus-
sions. Table 2 demonstrates how the model is able to
match target data when calibrating to the TB epidemic in
two divergent epidemiological settings, using South Africa
and Ghana as examples.
South Africa: link to policy and capacity building
In South Africa, TIME Impact has been applied to pro-
vide evidence for the TB component of the country’s
first-ever TB investment case, where the modelling re-
sults are instrumental in informing governmental TB
spending from 2016 onwards. Figure 4 shows modelled
outputs for baseline incidence and mortality of the TB
epidemic in South Africa. The software tool has also
been used as part of a South African capacity building
project at the national and provincial level, which aims
to integrate the use of a modelling framework into sub-
national TB policy discussions. This local ownership and
direct link to policy stands in contrast to other models
that have investigated TB epidemiology and interven-
tions in the South African context. While there is a sub-
stantial amount of modelling activity occurring in South
Africa [13, 14, 26], none of these are run directly by
locally-trained National or provincial TB Programme
members. This case study shows that, through local
Table 1 Data for TIME Impact
Included
• Demographic data and projections; UN Population Division
• Global Tuberculosis Programme (GTB) estimates for incidence,
prevalence, mortality, notifications; GTB
• HIV burden and antiretroviral therapy (ART) coverage; UNAIDS
Required
• Estimated number of individuals screened (preferably trends);
National Tuberculosis Programmes (NTPs)
• Diagnostic algorithms and coverage; NTP
• Linkage to care (trends, by multidrug resistance (MDR)); NTP, literature
(MDR, GTB)
• Treatment success, by MDR (trends); GTB
• Drug susceptibility testing coverage; GTB
Desirable
• Prevalence survey results; NTP
• Drug resistance survey results; NTP
• HIV prevalence + ART coverage (required if high HIV burden setting);
GTB, NTP
• Proportion of tuberculosis (TB) in children (<15 years old); NTP
• Current coverage and efficacy of TB programme activities; NTP
• Size of risk groups and TB prevalence; NTP
Table provides a non-exhaustive list of data used to inform TIME Impact and
suggested sources. ‘Included’ data are automatically provided by Spectrum,
whereas those listed under ‘required’ and ‘desirable’ need to be provided by
the user
Table 2 Model fit to calibration targets
South Africa Ghana
Target (2012) Model Target (2013) Model
Notifications rate (per 100,000) 667 622.7 61.9 60.3
Prevalence rate (per 100,000) 705 (388–1114) 662 290 (113–548) 312
Incidence rate (per 100,000) 900 (832–990) 892 168 (81–286) 167
Mortality rate (per 100,000) 179 (149–212) 191 52 (24.8–88) 64.6
% prevalence MDR (treatment naïve) 1.8 (1.5–2.3)a 1.7 1.9 (0.1–5.3) 2.9
% prevalence MDR (retreatment) 6.7 (5.5–8.1)a 6.1 20 (0.1–40) 13.7
15+ HIV prevalence 15 (14–16) 15.4 1.5 (1.2–2.0) 1.34
ART coverage 36 (34–39) 34 32 (24–41) 27.5
a South Africa MDR prevalence based on 2002 survey data
ART, Antiretroviral therapy; MDR, Multidrug resistance
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ownership, we can better influence decision making, for
example through additional funding for TB in 2017–2019
as part of a combined TB/HIV conditional grant.
Ghana: reprogramming the TB response
In 2013, Ghana undertook a national TB prevalence survey
which showed a generalised epidemic that is four times
higher than previously estimated (all forms prevalence 290
vs. 71 per 100,000). The initial focus of the operational plan
was to shift from passive screening towards active case
finding in high-risk groups.
The TIME modelling framework was applied in-country
to support decision-making and setting priorities within the
NTP and the Global Fund Country Team. This work is part
of an on-going collaboration with in-country policymakers
and international stakeholders as the NTP goes through the
process of reprogramming their national response.
Discussions around the TIME Impact modelling results
informed during the grant-making phase of the Global
Fund’s New Funding Model. The discussions were contin-
ued through repeated visits to establish a long-term col-
laboration with the NTP and provide continued support
along the New Funding Model process (Fig. 5).
The TIME modelling framework was used to provide a
clear understanding of the current and future epidemic,
given the new prevalence survey results and in the absence
of further action (Fig. 6). This showed that, in the absence
of additional NTP activities, the prevalence of TB remains
stable and may even increase in future years.
The TIME Impact modelling results highlighted a high
risk of not reaching the ambitious national notification
targets stated in the country’s performance framework as
part of the Global Fund grant. The application of the
TIME modelling framework in-country contributed to
the decisions to shift focus of available resources from
active screening in high-risk groups towards improving
clinic-based screening and an expansion in coverage
from 42 % to 100 % of districts.
(A) TB Incidence
(B) Mortality
Fig. 4 Model outputs for tuberculosis (TB) incidence and mortality in South Africa. The calibration focussed on matching 2012 data and
aimed to fit within the confidence intervals around the Global TB Programme (GTB) estimates (thin solid lines). a TB Incidence: Modelled
incidence (thick solid line) closely matches GTB estimates (dotted line). Model matches disaggregation by HIV status and annual decline in
incidence in 2012. b Mortality: Modelled mortality (thick solid lines) match GTB estimates in 2012 (dotted line)
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(A) Notifications
(B) Prevalence
Fig. 6 Model outputs for notifications and prevalence in Ghana. a Notifications: Total notifications from model (thin solid line) closely match
Global Tuberculosis Programme data (black dots). TIME Impact estimates the positive predictive value amongst notifications to be 75 %. True
positive notifications are shown in the dark blue shaded area and false positive notifications are shown in shaded light blue. b Prevalence: Model
was calibrated to adult prevalence estimates from the 2013 national prevalence survey (squares). Modelled smear positive adult prevalence is
represented in red and all forms adult prevalence is represented in blue
Fig. 5 Global Fund to Fight AIDS, Tuberculosis and Malaria New Funding Model and country engagement timeline. TRP, Technical review panel;
GAC, Grant approval committee. Figure adapted from the Global Fund to show visits to Ghana along the New Funding Model
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The TIME modelling framework is continuing to be
applied as the Ghana NTP moves towards implementa-
tion of their reprogrammed response.
Other country-support experiences
In addition to these examples, TIME Impact has been
applied in various other country collaborations, in par-
ticular for the purpose of strengthening the case for
investment in country’s Concept Notes for GFATM
applications, e.g. for Sudan, Bangladesh and Viet Nam. In
Viet Nam, TIME Impact contributed to the narrative of
the Concept Note to the GFATM, which was highly
successful.
Impact evaluation of implementing TIME
Identifying the specific programmatic effect of a policy
change is both critical as well as challenging, further
compounded by the complexity of attributing part of
that effect to a specific input to the complicated policy
process. Efforts are currently underway to quantify the
impact from implementing TIME in Ghana and South
Africa, results of which are expected in the coming years.
Future development
While the country-examples show that TIME Impact has
been useful in its current form, development is ongoing to
expand the model functionalities in line with feedback from
users and policymakers, and address current limitations.
One key limitation of the current version of the TIME
Impact tool is the assumption of homogenous mixing.
While common in epidemiological models of TB, there
are notable exceptions around age-specific mixing [27]
and poverty [28]. Development is ongoing to introduce
the facility in TIME Impact, which would process infor-
mation on the relative burden of TB in the general and
at-risk population and the mechanism behind this higher
burden and, critically, the level of contact between groups
[28]. Further, as extensive drug resistance becomes an in-
creasingly large problem, we will look to extend our drug-
resistant strata to include the development of extensively
drug-resistant TB.
Finally, all epidemiological modelling results are un-
certain and it is important to convey this uncertainty to
policymakers [6]. Development is ongoing for an auto-
mated framework to facilitate fitting the model to epi-
demiological data and generating uncertainty bounds
around results introduced by assumptions regarding nat-
ural history, epidemiological data, the epidemiological
effect of interventions and what happens in the future.
Another key area of interest is capturing the epidemio-
logical impact of socioeconomic trends and structural
determinants in the population. The End TB Strategy
places increased emphasis on these issues [29], but gaps
in both data and technical understanding currently
prohibit confident modelling and this is not currently pos-
sible in TIME Impact. Future model and knowledge devel-
opment should allow us to incorporate such functionality
in due time.
Costing and resource allocation
Strategic planning requires relating the cost of TB inter-
ventions to their epidemiological impact. National TB
Programmes, Ministries of Health and Finance, NGOs
and international donors must be able to formulate and
answer a variety of questions about the relative impact
of different intervention scenarios in order to maximize
allocative efficiency, estimate cost effectiveness metrics such
as cost per disability-adjusted life year or death averted, and
accurately estimate the budget requirements and funding
gaps associated with meeting strategic targets or imple-
menting new programmes.
TIME Impact and TIME Estimates are linked to the
OneHealth Tool, a comprehensive costing and budgeting
tool developed by a group of UN agencies, including
WHO, UNAIDS, UNDP, UNFPA, UNICEF and the
World Bank. OneHealth provides a single framework for
planning, costing, impact analysis, budgeting and finan-
cing of strategies for major diseases and health system
components. OneHealth’s TB costing module is designed
to mimic the WHO TB Planning and Budgeting Tool, a
detailed ingredients-based costing tool developed by the
Global TB Programme [30]. Users can control the cover-
ages of diagnostic, treatment and patient support inter-
ventions over time, modify the population targeted to
receive each intervention, cost the construction of new
laboratories, and match budget lines to fit with national
or international funder requirements.
Development of a new TIME Economics module is
currently underway. TIME Economics is intended to ad-
dress TB-specific allocative efficiency and cost-effectiveness
questions.
Conclusion
In summary, the TIME Impact software tool is now
available and has advanced the field of modelling to
support TB policy discussions at country level. As de-
velopment continues in collaboration with stakeholders
from the TB community, the focus remains to integrate
capacity building with generating modelling results that
have a high local ownership, now considered for policy
discussions at the national and sub-national levels.
Additional file
Additional file 1: TIME Impact Technical Appendix. (PDF 783 kb)
Competing interests
The authors declare that they have no competing interests.
Houben et al. BMC Medicine  (2016) 14:56 Page 9 of 10
Authors’ contributions
RMGJH, CP and RGW had the idea for the study. RMGHJ and CP led the
development of the model. ML, TS, DP, MH and RGW contributed to the
development and implementation of the model. FB, PH and YP supported
country implementation of TIME Impact. MK and SA provided guidance on
development and implementation. RMGJH and ML wrote the first draft of
the manuscript. All authors provided comments on the submitted manuscript.
Acknowledgments
The authors acknowledge the comments, suggestions and fruitful discussions
from representatives from various organisations that have contributed to the
development and implementation of TIME over the past years, in particular
representatives from the National TB Programmes that have used TIME, and
individual members from the TB Modelling and Analysis Consortium, whose
feedback on the model design and functionality has greatly helped to improve
TIME Impact.
Funding
This work was funded by a grant from USAID (sub-award from The Union
America, TREAT-TB grant, grant code GHN-A-00-08-00004-00) and Bill & Melinda
Gates Foundation (grant code OPP1084276). The funder (SA) provided input on
the manuscript, which remains the responsibility of the lead authors. RGW is
also funded the UK Medical Research Council (MRC) and the UK Department for
International Development (DFID) under the MRC/DFID Concordat agreement
that is also part of the EDCTP2 programme supported by the European Union
(MR/J005088/1), and the Bill & Melinda Gates Foundation (TB Modelling and
Analysis Consortium: OPP1084276, and SA Modelling for Policy: #OPP1110334).
The contents of this document are the sole responsibility of the authors
and can under no circumstances be regarded as reflecting the positions of
the International Union Against Tuberculosis and Lung Disease (The Union
North America) nor those of the Donors.
Author details
1TB Modelling Group, TB Centre, London School of Hygiene and Tropical
Medicine, Keppel Street, WC1E 7HT, London, UK. 2Department of Infectious
Disease Epidemiology, London School of Hygiene and Tropical Medicine,
London, UK. 3Avenir Health, Glastonbury, CT, USA. 4National Tuberculosis
Control Programme, Ghana Health Service, Accra, Ghana. 5Aurum Institute,
Johannesburg, South Africa. 6National Department of Health, Pretoria, South
Africa. 7KNCV Tuberculosis Foundation, The Hague, The Netherlands. 8USAID,
Washington, DC, USA.
Received: 16 January 2016 Accepted: 22 March 2016
References
1. World Health Organisation. Global Tuberculosis Report 2015. Geneva: WHO; 2015.
2. Lonnroth K, Glaziou P, Weil D, Floyd K, Uplekar M, Raviglione M. Beyond
UHC: monitoring health and social protection coverage in the context of
tuberculosis care and prevention. PLoS Med. 2014;11:e1001693.
3. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of
tuberculosis epidemics: the role of risk factors and social determinants.
Soc Sci Med. 2009;68(12):2240–6.
4. World Health Assembly. Post-2015 Global TB Strategy and Targets (A67/62).
Geneva: WHO; 2014.
5. Leach-Kemon K, Chou DP, Schneider MT, Tardif A, Dieleman JL, Brooks BP,
et al. The global financial crisis has led to a slowdown in growth of funding
to improve health in many developing countries. Health Aff. 2012;31(1):228–35.
6. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models
in the evaluation of health programmes. Lancet. 2011;378(9790):515–25.
7. Walker N, Tam Y, Friberg IK. Overview of the Lives Saved Tool (LiST). BMC
Public Health. 2013;13 Suppl 3:S1.
8. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model:
user friendly version 3.0. Diabetes Res Clin Pract. 2000;50 Suppl 3:S15–46.
9. Stover J, Johnson P, Hallett T, Marston M, Becquet R, Timaeus IM. The
Spectrum projection package: improvements in estimating incidence by
age and sex, mother-to-child transmission, HIV progression in children and
double orphans. Sex Transm Infect. 2010;86 Suppl 2:ii16–21.
10. Stover J, McKinnon R, Winfrey B. Spectrum: a model platform for linking
maternal and child survival interventions with AIDS, family planning and
demographic projections. Int J Epidemiol. 2010;39 Suppl 1:i7–10.
11. OECD Development Assistance Committee. The Paris Declaration on Aid
Effectiveness. Paris: OECD; 2005.
12. Knight GM, Dharan NJ, Fox GJ, Stennis N, Zwerling A, Khurana R, Dowdy DW.
Bridging the gap between evidence and policy for infectious diseases: How
models can aid public health decision-making. Int J Infect Dis. 2016;42:17–23.
13. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid
diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden
countries: a cost-effectiveness analysis. PLoS Med. 2011;8(11):e1001120.
14. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health
impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF:
a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.
15. Trauer JM, Denholm JT, McBryde ES. Construction of a mathematical model
for tuberculosis transmission in highly endemic regions of the Asia-Pacific.
J Theor Biol. 2014;358:74–84.
16. Sachdeva KS, Raizada N, Gupta RS, Nair SA, Denkinger C, Paramasivan CN, et al.
The potential impact of up-front drug sensitivity testing on India’s epidemic of
multi-drug resistant tuberculosis. PLoS One. 2015;10(7):e0131438.
17. Dowdy DW, Andrews JR, Dodd PJ, Gilman RH. A user-friendly, open-source
tool to project impact and cost of diagnostic tests for tuberculosis. Elife.
2014;3:e02565.
18. Nishikiori N, Van Weezenbeek C. Target prioritization and strategy selection
for active case-finding of pulmonary tuberculosis: a tool to support country-
level project planning. BMC Public Health. 2013;13:97.
19. ScreenTB - target prioritization and strategy selection for tuberculosis
screening (active case finding). https://wpro.shinyapps.io/screen_tb/.
Accessed December 2015.
20. Pretorius C, Glaziou P, Dodd PJ, White R, Houben R. Using the TIME model
in Spectrum to estimate tuberculosis-HIV incidence and mortality. AIDS.
2014;28 Suppl 4:S477–87.
21. Dowdy DW, Dye C, Cohen T. Data needs for evidence-based decisions: a
tuberculosis modeler’s ‘wish list’. Int J Tuberc Lung Dis. 2013;17(7):866–77.
22. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood
tuberculosis in 22 high-burden countries: a mathematical modelling study.
Lancet Glob Health. 2014;2(8):e453–9.
23. Joint Assessment of National Health Strategies and Plans Inter-Agency Working
Group. Joint Assessment Tool: the attributes of a sound national strategy. Vol.
2. 2011. http://www.who.int/workforcealliance/knowledge/toolkit/24_1.pdf.
24. Buse K, Mays N, Walt G. Making Health Policy. London: Open University
Press; 2005.
25. Cookson R. Evidence-based policy making in health care: what it is and
what it isn’t. J Health Serv Res Policy. 2005;10(2):118–21.
26. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, et al.
Prevention of nosocomial transmission of extensively drug-resistant
tuberculosis in rural South African district hospitals: an epidemiological
modelling study. Lancet. 2007;370(9597):1500–7.
27. Suen SC, Bendavid E, Goldhaber-Fiebert JD. Cost-effectiveness of
improvements in diagnosis and treatment accessibility for tuberculosis
control in India. Int J Tuberc Lung Dis. 2015;19(9):1115–24. i-xv.
28. Andrews JR, Basu S, Dowdy DW, Murray MB. The epidemiological advantage
of preferential targeting of tuberculosis control at the poor. Int J Tuberc
Lung Dis. 2015;19(4):375–80.
29. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al.
WHO’s new End TB Strategy. Lancet. 2015;385:1799–801.
30. Planning and Budgeting Tool for TB Control. http://www.who.int/tb/dots/
planning_budgeting_tool/en/. Accessed 14 January 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Houben et al. BMC Medicine  (2016) 14:56 Page 10 of 10
